DISCOUNT ZERTIFIKAT - AMGEN | Real-time Bid/Ask 12:52:29 2024-07-17 pm EDT | ||
| 209.05 EUR / 209.15 EUR | -0.26% |
|
| Current month | -1.15% | ||
| 1 month | -1.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 208.9 | -0.36% |
| 24-07-16 | 209.6 | +0.04% |
| 24-07-15 | 209.6 | +0.14% |
| 24-07-12 | 209.3 | -0.30% |
| 24-07-11 | 209.9 | -0.37% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 10:24 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME680N |
| ISIN | DE000ME680N3 |
| Date issued | 2024-01-02 |
| Maturity | 2024-09-20 (65 Days) |
| Parity | 1 : 1 |
| Emission price | 200 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 213.1 € |
|---|---|
| Lowest since issue | 196.9 € |
| Spread | 0.1 € |
| Spread % | 0.05% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
333.1
USD
Average target price
317.4
USD
Spread / Average Target
-4.72%
- Stock Market
- Certificates
- Certificat
